Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement
Executive Summary
Biogen's strategy to meet its Amevive (alefacept) 2003 sales target includes increasing the physician referral rate and shortening the time needed for patients to secure reimbursement
You may also be interested in...
Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain
Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Elan expects to return to profitability in 2005 with the potential launches of Antegren for multiple sclerosis and Crohn's disease and Prialt for chronic pain
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive